FDA approves satralizumab (Enspryng) for Neuromyelitis Optica Spectrum Disorder

Approval for this anti-IL-6 receptor monoclonal antibody is based on results from two phase III studies which demonstrated significantly reduced risk of relapse vs placebo (SAkuraSky; n=168; 30% vs 50%; HR 0.38, 95% CI 0.16-0.88 & SAkuraStar; n=83; 20% vs 43%, 0.45, 0.23-0.89).

Source:

Biospace Inc.